Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q3 EPS of ($0.37), $0.09 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $951 thousand.

For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.